推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to light brown
溶解度
H2O: 25 mg/mL, clear
儲存溫度
−20°C
InChI
1S/C24H38N6/c1-2-13-29-24(5-1)20-28-19-22-6-8-23(9-7-22)21-30-17-4-12-26-15-14-25-10-3-11-27-16-18-30/h1-2,5-9,13,25-28H,3-4,10-12,14-21H2
InChI 密鑰
CWJJHESJXJQCJA-UHFFFAOYSA-N
生化/生理作用
AMD3465 is a highly selective chemokine receptor CXCR4 antagonist with antiviral and anticancer activity. The chemokine receptor CXCR4 is expressed on a wide variety of leukocytes and is the predominant receptor for stromal cell-derived factor-1 (SDF1, CXCL12) in addition to acting as a co-receptor for HIV entry into cells. AMD3465 blocks surface binding of CXCL12 (SDF-1α). AMD3465 is an antagonist of SDF-1 ligand binding (K(i) of 41.7+/-1.2 nM). AMD3465 was found to halt the progression of an agressive childhood blood cancer, T-cell acute lymphoblastic leukemia (T-ALL), within two weeks of starting treatment in an animal model.
AMD3465 is also termed as{N-[1,4,8,11-tetraazacyclotetradecanyl-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine}. It controls oncogenic signaling and invasiveness in vitro. It inhibits breast cancer growth and metastasis in vivo. As a chemokine receptor 4 (CXCR4) antagonist, AMD3465 is ten times more efficient than bicyclam AMD3100.
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Imaging CXCR4 Expression in Human Cancer Xenografts: Evaluation of Monocyclam 64Cu-AMD3465
Journal of Nuclear Medicine, 52(6), 986-986 (2011)
The CXCR4 Antagonist AMD3465 Regulates Oncogenic Signaling and Invasiveness In Vitro and Prevents Breast Cancer Growth and Metastasis In Vivo
PLoS ONE, 8(3), e58426-e58426 (2013)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门